Document is current

Article History

Accepted: 3 January 2023

First Online: 9 February 2023

Declarations

:

: This study was funded by CSL Behring.

: Rajiv Mallick is an employee of CSL Behring and holds stock options. Rashad Carlton and Joris Van Stiphout are employees of Xcenda, which received funding from CSL Behring for this analysis.

: Data for the model were obtained from a variety of sources, including published studies, publicly available costs and databases, and assumptions as necessary.

: As this was an economic analysis that did not use any identifiable patient data, no ethics approval was required.

: Not applicable.

: Not applicable.

: An unlocked version of the model has been provided as ESM. The input parameters specific to the US-approved labeling for Hizentra, including dosing and relapse parameters, are not modifiable. The VBA coding is proprietary to the model developers and is not publicly available.

: Conceptualization: RM, RC, and JVS. Methodology: RM, RC, and JVS. Formal analysis: RM, RC, and JVS. Writing, review, and editing: RM, RC, and JVS.